RecruitingNot ApplicableNCT07271927

Whole-Body Photobiomodulation for Motor and Cognitive Changes in Parkinson's Disease

Evaluation Study of the Effects and Safety of Whole-Body Photobiomodulation Therapy on Motor and Cognitive Changes in Patients With Parkinson's Disease


Sponsor

Pusan National University Yangsan Hospital

Enrollment

15 participants

Start Date

Feb 12, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to exploratorily evaluate the extent of motor and cognitive changes, as well as the safety, resulting from approximately 10 weeks of whole-body photobiomodulation (PBM) therapy (about three sessions per week, once daily, 20 minutes per session) in patients with Parkinson's disease.


Eligibility

Min Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whole-body photobiomodulation therapy — a treatment that uses specific wavelengths of light delivered over the entire body — to see if it can improve movement and thinking in people with Parkinson's disease. **You may be eligible if...** - You are 40 years or older - You have been diagnosed with Parkinson's disease at a mild to moderate stage (Hoehn and Yahr stages 1–3) - You are able to walk independently without a mobility aid **You may NOT be eligible if...** - You have severe cognitive impairment (very low score on a standard memory test) - You have had deep brain stimulation (DBS) surgery - You have light-sensitive skin conditions or are taking medications that cause sensitivity to light - You have severe medical conditions that prevent participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPhotobiomodulation

Participants received whole-body PBM therapy over approximately 10 weeks (three sessions per week, once daily, 20 minutes per session), with each session using a randomly selected wavelength of either 660 nm, 850 nm, or 940 nm (±20%).


Locations(1)

Pusan National University Yangsan Hospital

Yangsan, Gyeongsangnam-do, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07271927


Related Trials